Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Three-arm Phase 2 Study Evaluating Two Dose Levels of Microneedle-mediated Delivery of Doxorubicin Compared With a Device-only Control in Patients With Nodular Basal Cell Carcinoma.

NCT06608238 is registered in ClinicalTrials.gov with SkinJect, Inc. as lead sponsor.

NCT NCT06608238
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06608238 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Three-arm Phase 2 Study Evaluating Two Dose Levels of Microneedle-mediated Delivery of Doxorubicin Compared With a Device-only Control in Patients With Nodular Basal Cell Carcinoma.
Lead sponsor
SkinJect, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 3, 2024
Completion date
March 13, 2026
Enrollment
90 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

nodular basal cell carcinoma